These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 22607479)

  • 41. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma.
    Scicchitano R; Aalbers R; Ukena D; Manjra A; Fouquert L; Centanni S; Boulet LP; Naya IP; Hultquist C
    Curr Med Res Opin; 2004 Sep; 20(9):1403-18. PubMed ID: 15383189
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-life use of budesonide/formoterol in clinical practice: a 12-month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy.
    Ställberg B; Naya I; Ekelund J; Eckerwall G
    Int J Clin Pharmacol Ther; 2015 Jun; 53(6):447-55. PubMed ID: 25907171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative effectiveness of budesonide-formoterol combination and fluticasone-salmeterol combination for asthma management: a United States retrospective database analysis.
    Tunceli O; Williams SA; Kern DM; Elhefni H; Pethick N; Wessman C; Zhou S; Trudo F
    J Allergy Clin Immunol Pract; 2014; 2(6):719-26. PubMed ID: 25439363
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life.
    Price DB; Williams AE; Yoxall S
    Respir Res; 2007 Jul; 8(1):46. PubMed ID: 17610727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist.
    Yang HH; Lai CC; Wang YH; Yang WC; Wang CY; Wang HC; Chen L; Yu CJ
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2477-2485. PubMed ID: 28860742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Baseline Characteristics and Maintenance Therapy Choice on Symptom Control, Reliever Use, Exacerbation Risk in Moderate-Severe Asthma: A Clinical Modelling and Simulation Study.
    Paggiaro P; Garcia G; Roche N; Verma M; Plank M; Oosterholt S; Duong JK; Majumdar A; Della Pasqua O
    Adv Ther; 2024 Nov; 41(11):4065-4088. PubMed ID: 39240503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics.
    Tarsin WY; Pearson SB; Assi KH; Chrystyn H
    Int J Pharm; 2006 Jun; 316(1-2):131-7. PubMed ID: 16584855
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma.
    Aubier M; Pieters WR; Schlösser NJ; Steinmetz KO
    Respir Med; 1999 Dec; 93(12):876-84. PubMed ID: 10653049
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy.
    Hozawa S; Terada M; Haruta Y; Hozawa M
    Pulm Pharmacol Ther; 2016 Apr; 37():15-23. PubMed ID: 26850307
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma.
    Dahl R; Chuchalin A; Gor D; Yoxall S; Sharma R
    Respir Med; 2006 Jul; 100(7):1152-62. PubMed ID: 16675212
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Achieving asthma control with ICS/LABA: A review of strategies for asthma management and prevention.
    Aalbers R; Vogelmeier C; Kuna P
    Respir Med; 2016 Feb; 111():1-7. PubMed ID: 26614594
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination budesonide/formoterol inhaler as maintenance and reliever therapy in Māori with asthma.
    Pilcher J; Patel M; Smith A; Davies C; Pritchard A; Travers J; Black P; Weatherall M; Beasley R; Harwood M;
    Respirology; 2014 Aug; 19(6):842-51. PubMed ID: 24889937
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-world effects of two inhaled corticosteroid/long-acting β₂-agonist combinations in the treatment of asthma.
    Yatera K; Yamasaki K; Nishida C; Noguchi S; Oda K; Akata K; Nagata S; Kawanami Y; Kawanami T; Ishimoto H; Mukae H
    J Asthma; 2014 Sep; 51(7):762-8. PubMed ID: 24654703
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma.
    Bisgaard H; Le Roux P; Bjåmer D; Dymek A; Vermeulen JH; Hultquist C
    Chest; 2006 Dec; 130(6):1733-43. PubMed ID: 17166990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study.
    FitzGerald JM; Sears MR; Boulet LP; Becker AB; McIvor AR; Ernst P; Smiljanic-Georgijev NM; Lee JS;
    Can Respir J; 2003; 10(8):427-34. PubMed ID: 14679407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Simulation Study of the Effect of Clinical Characteristics and Treatment Choice on Reliever Medication Use, Symptom Control and Exacerbation Risk in Moderate-Severe Asthma.
    Garcia G; van Dijkman SC; Pavord I; Singh D; Oosterholt S; Fulmali S; Majumdar A; Della Pasqua O
    Adv Ther; 2024 Aug; 41(8):3196-3216. PubMed ID: 38916810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease.
    Nannini LJ; Poole P; Milan SJ; Kesterton A
    Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD006826. PubMed ID: 23990350
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
    Markham A; Jarvis B
    Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study.
    Aalbers R; Brusselle G; McIver T; Grothe B; Bodzenta-Lukaszyk A
    Adv Ther; 2012 Nov; 29(11):958-69. PubMed ID: 23081745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.